



A Novel, Non-Addictive Analgesic

Tuleviate


- Created by the lab of James Zadina, PhD
- Safer, **non-addictive** analgesic with peripheral and central mechanisms
- Long-lasting efficacy across **acute, inflammatory, neuropathic, postoperative, and visceral pain**
- **Decreased risk** of tolerance and respiratory depression versus morphine
- **Flexible administration** (oral IV, subcutaneous), **high stability, and scalable manufacturing**
- **Blocks withdrawal symptoms and relapse** when substituted for traditional opioids

Tuleviate NextGen


- **Glycosylated analogs** show enhanced blood-brain barrier penetration, higher potency, and longer analgesia
- Retain favorable safety profile and decreased addiction potential

Why partner with Tulane?

- VA and NIDA funded
- **Strong IP**, collaborative lab
- Open to co-development, licensing, and sponsored research



Tuleviate produced longer analgesia in neuropathic pain compared with morphine, even after chronic administration



Compared with traditional opioids, Tuleviate does not induce addictive or reward-seeking behaviors

For inquiries, contact:
 Alexis Ducote, PhD
 Business Development Associate
aducote@tulane.edu
 337.540.4025